Topiramate (All indications) updated on 04-22-2025

Cognitive developmental disorders/delay (< 3 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16627
R69718		 Thomas (Topiramate) (Epilepsy) (Controls exposed to LTG), 2022 The mental development quotient (MEDQ) - The developmental assessment scale for Indian infants (DASII) - Between 12-24 months of age (mean (SD): 15.3 (3.9) months)) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No extrapolated (cont. endpoint) 1.08 [0.21;5.38]
excluded (control group) 		-/6   -/26 - 6
ref
S16628
R69720		 Thomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022 The mental development quotient (MEDQ) - The developmental assessment scale for Indian infants (DASII) - Between 12-24 months of age (mean (SD): 15.3 (3.9) months)) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No extrapolated (cont. endpoint) 1.05 [0.24;4.64] -/6   -/110 - 6
ref
Total 1 studies 1.05 [0.24;4.62] 0 6
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022Thomas, 2022 1 1.05[0.24; 4.64]-60%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: lowROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Epilepsy) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.05[0.24; 4.62]-6 -NAThomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.05[0.24; 4.62]-6 -NAThomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022 1 Tags Adjustment   - No  - No 1.05[0.24; 4.62]-6 -NAThomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 1.05[0.24; 4.62]-6 -NAThomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022 1 All studiesAll studies 1.05[0.24; 4.62]-6 -NAThomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16627

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.05[0.24; 4.62]-6 -NAThomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.08[0.21; 5.47]-6 -NAThomas (Topiramate) (Epilepsy) (Controls exposed to LTG), 2022 10.510.01.0